{"id":"W4378781365","doi":"10.1080/21678421.2023.2216223","title":"COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success","year":2023,"lang":"en","type":"article","venue":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Alberta; Montreal Neurological Institute and Hospital","funders":"Grupo Ferrer Internacional, S.A; Astellas Pharma; Motor Neurone Disease Association; National Institute for Health and Care Research; University of Alberta; Apellis Pharmaceuticals; King's College London; Denali Therapeutics; Mitsubishi Tanabe Pharma Corporation; Agence Nationale de la Recherche; Hope Foundation; Acorda Therapeutics; Pfizer; UCB Pharma; Fondation Brain Canada; Medical Research Council; Biogen; Cytokinetics; Economic and Social Research Council; Deutsche Gesellschaft für Neurologie; Sanofi; Alexion Pharmaceuticals","keywords":"Physical therapy; Medicine; Population; Rating scale; Clinical trial; Amyotrophic lateral sclerosis; Courage; Placebo; Randomized controlled trial; Psychology; Disease; Internal medicine; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002296717,0.000354279,0.0009808945,0.0001593198,0.0003913325,0.0002205786,0.0001916974,0.0001356,0.0000658552],"category_scores_gemma":[0.0002327637,0.00021083,0.0001328894,0.0005683163,0.0004792255,0.0004030404,0.0002630803,0.0002256128,0.00001038045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007863447,"about_ca_system_score_gemma":0.00009786968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005657687,"about_ca_topic_score_gemma":0.0002688923,"domain_scores_codex":[0.9962971,0.0006513234,0.0009959905,0.0007627627,0.0007342877,0.0005585392],"domain_scores_gemma":[0.9982723,0.000160128,0.0002307919,0.0005646148,0.0003041652,0.0004680233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.3509273,0.002000078,0.07354399,0.0002632191,0.000522027,0.0000593022,0.01856647,0.0002749918,0.5390905,0.0005364809,0.0003664407,0.0138492],"study_design_scores_gemma":[0.4327304,0.00475437,0.5215734,0.0002912193,0.0006677048,0.0000178026,0.0008071032,0.02456903,0.01327807,0.0005372728,0.00003639503,0.0007372259],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906494,0.0002743711,0.0002526164,0.002591383,0.000124096,0.005983543,0.00002428451,0.00008472586,0.0000155872],"genre_scores_gemma":[0.9973069,0.0002403593,0.0003266924,0.0001826711,0.0001752642,0.001492427,0.00004602538,0.00003514897,0.0001944611],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5258124,"threshold_uncertainty_score":0.8597397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1337870059088949,"score_gpt":0.3642564715540338,"score_spread":0.2304694656451389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}